| Literature DB >> 31883994 |
Kenneth W Finnson1, Yasser Almadani1, Anie Philip2.
Abstract
Transforming growth factor (TGF)-β uses several intracellular signaling pathways besides canonical ALK5-Smad2/3 signaling to regulate a diverse array of cellular functions. Several of these so-called non-canonical (non-Smad2/3) pathways have been implicated in the pathogenesis of fibrosis and may therefore represent targets for therapeutic intervention. This review summarizes our current knowledge on the mechanisms of non-canonical TGF-β signaling in fibrosis, the potential molecular targets and the use of agonists/antagonists for therapeutic intervention.Entities:
Keywords: Fibrosis; Non-nanonical; Scleroderma; TGF-beta; non-Smad
Year: 2019 PMID: 31883994 DOI: 10.1016/j.semcdb.2019.11.013
Source DB: PubMed Journal: Semin Cell Dev Biol ISSN: 1084-9521 Impact factor: 7.727